You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

115 Results
Guidelines and Advice
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Jun 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024
Drug
Other Name(s): Piqray®
Jun 2024
Guidelines and Advice
Status: In-Review
ID: 4-3
Version: 4
Jul 2017

Pages